News

A study compared the efficacy of febuxostat and benzbromarone in treating gout, emphasizing the lack of consensus in previous research and the need for future, well-designed studies.

Compared to routine care, TCMD could better reduce the incidence of adverse events and the level of laboratory indicators.

Significant differences in the practice of primary healthcare physicians were observed based on medical specialty when treating and managing asymptomatic hyperuricemia and gout.

As gastrointestinal (GI) symptoms are common in the US, how does rheumatoid arthritis (RA) affect the frequency of GI events? Test your knowledge with this quiz.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Results indicated patients with GERD are at a 69% increased risk of developing RA.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

The PETRA questionnaire proves valuable in assessing the transition readiness of juvenile idiopathic arthritis patients into adult care, with a focus on self-management skills.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.

Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.

Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.

Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.

Results showed treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) improved bone mineral density and reduced osteoporosis risk in patients with type 2 diabetes.

Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.

Laura Donlin, PhD, highlights the significance of identifying new subtypes of rheumatoid arthritis, emphasizing the potential for a paradigm shift in RA treatment toward personalized care and early interventions.

Patients with gout who did not experience recurrent flares had a shorter mean time between diagnosis and the start of urate-lowering therapy compared with those who had ≥1 flare.

Patients with gout achieving target serum uric acid levels showed good adherence to urate-lowering therapy, used antihypertensive agents, and lacked a family history of gout.

This analysis resulted in several valuable insights related to the landscape of gout patients’ changes in their blood immune cells between flares and periods of remission.

Waist circumference and high lipid levels were associated with poor disease outcomes in gout, including flares and failure to achieve treatment target.

This new data expanded upon research into gout’s molecular pathogenesis and into ULT for managing non-gout diseases such as hyperuricemia.

Patients with the highest Dietary Inflammatory Index have an increased risk of gout.

A virtual screening combined with experimental verification identified the potential mechanism of fuzitang decoction in the treatment of Gouty Arthritis.

Nonsteroidal anti-inflammatory drug use and prednisolone equivalent dose >5 mg per day were associated with an increased risk of NAFLD, whereas hydroxychloroquine use and prednisolone equivalent dose ≤5 mg per day were associated with a decreased risk of NAFLD.